- Home
- CERO vs APDN Comparison
CERO vs APDN Comparison
Compare CERO & APDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- APDN
- Stock Information
- Founded
- CERO 2017
- APDN 1983
- Country
- CERO United States
- APDN United States
- Employees
- CERO N/A
- APDN N/A
- Industry
- CERO
- APDN Other Consumer Services
- Sector
- CERO
- APDN Consumer Discretionary
- Exchange
- CERO Nasdaq
- APDN Nasdaq
- Market Cap
- CERO 3.5M
- APDN 4.2M
- IPO Year
- CERO N/A
- APDN N/A
- Fundamental
- Price
- CERO $9.10
- APDN $4.56
- Analyst Decision
- CERO Strong Buy
- APDN
- Analyst Count
- CERO 2
- APDN 0
- Target Price
- CERO $45.00
- APDN N/A
- AVG Volume (30 Days)
- CERO 3.3M
- APDN 151.0K
- Earning Date
- CERO 08-13-2025
- APDN 08-07-2025
- Dividend Yield
- CERO N/A
- APDN N/A
- EPS Growth
- CERO N/A
- APDN N/A
- EPS
- CERO N/A
- APDN N/A
- Revenue
- CERO N/A
- APDN $3,790,616.00
- Revenue This Year
- CERO N/A
- APDN $57.08
- Revenue Next Year
- CERO N/A
- APDN $40.00
- P/E Ratio
- CERO N/A
- APDN N/A
- Revenue Growth
- CERO N/A
- APDN N/A
- 52 Week Low
- CERO $6.71
- APDN $4.37
- 52 Week High
- CERO $895.40
- APDN $2,655.00
- Technical
- Relative Strength Index (RSI)
- CERO 46.88
- APDN 33.61
- Support Level
- CERO $8.12
- APDN $4.51
- Resistance Level
- CERO $11.68
- APDN $5.20
- Average True Range (ATR)
- CERO 2.74
- APDN 0.52
- MACD
- CERO 0.14
- APDN 0.45
- Stochastic Oscillator
- CERO 12.04
- APDN 26.36
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About APDN Applied DNA Sciences Inc.
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.